Genetic loss or pharmacologic inactivation of Ppm1d rendered primary leukemia cells more sensitive to the cytotoxic therapies used for AML, whereas activation of Ppm1d conferred a resistance phenotype. This evidence concerns the gene PPM1D and leukemia.